Leerink assumed coverage of AbCellera (ABCL) with an Outperform rating and $5 price target The firm likes AbCellera’s pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera Biologics Holds Annual Shareholder Meeting
- Unusually active option classes on open June 11th
- AbCellera Biologics Receives Health Canada Approval for Trial
- AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial
- AbCellera price target lowered to $10 from $28 at Truist